Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC

This study is testing whether giving camrelizumab (an immunotherapy drug) combined with chemotherapy before surgery can improve outcomes for patients with resectable stage IIIA–IIIB non-small cell lung cancer (NSCLC). Giving treatment before surgery (called neoadjuvant therapy) may shrink the tumor and improve the chance of a complete surgical removal. **You may be eligible if...** - You are between 18 and 75 years old - You have confirmed resectable stage IIIA–IIIB (T3–4N2) non-small cell lung cancer - Your tumor does NOT have EGFR, ALK, or ROS1 gene mutations - Your general health is good (ECOG status 0–1) - Your blood counts and organ function meet the required levels **You may NOT be eligible if...** - You have had prior chemotherapy or immunotherapy - You have another active cancer - You have interstitial lung disease or non-infectious pneumonia - You have an active autoimmune disease being treated with systemic medications - You have significant heart or lung dysfunction that makes surgery unsafe - You have an active infection requiring systemic treatment Talk to your doctor to see if this trial is right for you.